MedTrace Logo

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

NCT02482454 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-08-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.

Conditions

Interventions

PROCEDURE

Radiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance

BIOLOGICAL

Cytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    lead OTHER

Principal Investigators

  • Changping Wu, M.D. · The First People's Hospital of Changzhou

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2030-07-31
Completion
2033-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482454 on ClinicalTrials.gov